Reality Check
AbbVie Overpromises
Sales targets for its non-Humira drugs seem unrealistic.
This article is for subscribers only.
AbbVie Inc. has gotten some wins lately. But it may be guilty of over-celebrating.
The company provided boosted long-term sales forecasts last week, commemorating strong third-quarter sales of its lead drug Humira and a deal with Amgen Inc. that will protect the drug's future. But as we've seen this earnings season, forecast overreach can come back to bite.